- Trial phase
- Phase 1/2
- Time to market
- VIR-5818 is in Phase 1/2 with primary completion estimated in April 2028. Even if successful, regulatory filing and approval would likely be several years beyond that, putting potential commercialization in the early 2030s at the earliest.
- Why 3/10
- VIR-5818 has no specific dated catalyst in the next ~12 months; management said it expects to present a "meaningful update at a future scientific conference" but gave no date, and the primary completion of the Phase 1 trial is April 2028. The drug is one of several pipeline assets at Vir, which has more advanced programs (Phase 3 hepatitis delta, VIR-5500 pivotal) that are the primary near-term value drivers.
The next catalyst for VIR-5818 is a data update at a future scientific conference, with no specific date announced. The program is being slowed by FDA-requested dose-optimization backfill cohorts under Project Optimus. Vir's near-term stock-moving catalysts are the Phase 3 ECLIPSE 1 hepatitis delta readout (expected Q4 2026) and VIR-5500 pivotal trial initiation (2027), not VIR-5818.
Price Chart
Executive Summary
VIR-5818 is an early-stage (Phase 1/2) HER2-targeted dual-masked T-cell engager being developed by Vir Biotechnology (NASDAQ: VIR) for solid tumors including breast and colorectal cancers. Initial Phase 1 data from January 2025 showed encouraging safety (no dose-limiting cytokine release syndrome) and early efficacy signals in heavily pretreated patients. However, as of the November 4, 2026 Q3 earnings update, the program is being slowed by FDA-required dose-optimization backfill cohorts under Project Optimus, pushing any meaningful data update to an unspecified future scientific conference. With primary completion estimated at April 2028 and no imminent binary catalyst, VIR-5818 is a minor near-term value driver for Vir relative to its more advanced hepatitis delta and prostate cancer programs.
How It Works
VIR-5818 is a bispecific T-cell engager (TCE) designed to treat HER2-positive cancers. It works like a molecular bridge: one end grabs onto HER2 proteins on the surface of cancer cells, and the other end grabs onto CD3 proteins on immune T cells, forcing the T cell to attack the cancer cell. The drug uses a "dual-masking" technology (PRO-XTEN) where the binding sites are covered by inert polymer chains that are only removed by enzymes found in the tumor environment. This keeps the drug inactive in healthy tissue, reducing side effects like cytokine release syndrome (a dangerous immune overreaction) that plague conventional T-cell engagers.
Trial Status
The first-in-human Phase 1/2 trial (NCT05356741) is actively recruiting and evaluating VIR-5818 as monotherapy and in combination with pembrolizumab across multiple HER2-expressing tumor types. Dose escalation is ongoing. Following FDA feedback aligned with Project Optimus, the company is adding monotherapy backfill cohorts in a more homogeneous patient population for dose optimization before providing a comprehensive data update. Initial Phase 1 data from January 2025 showed no dose-limiting CRS and tumor shrinkage in heavily pretreated patients, including MSS colorectal cancer.
The Two-Sided Case
Upcoming Catalysts
- Meaningful data update at a future scientific conference (no date specified)
- Completion of dose-optimization backfill cohorts under Project Optimus (timeline unclear)
- Primary completion of Phase 1 trial estimated April 2028
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Vir Biotechnology, Inc. 8-K VIR ·Originating report